Knockdown or pharmacological inhibition of HDAC8 increased the infiltration of CD8+ T cells and enhanced the therapeutic effect of PD-L1 blockade for HCC.132 Zhang et al. found that combined treatment of DNMT and EZH2 inhibitors inhibited proliferation of human HCC cells and upregulated antitumor immune response. Here, HDAC8 is linked to hepatocellular carcinoma.